Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138

Virology

Volumn 280, Issue 1, 2001, Pages 97-106

  Pelemans, Heidi ^a   Aertsen, Abram ^a   Van Laethem, Kristel ^a   Vandamme, Anne Mieke ^a   De Clercq, Erik ^a   Pérez Pérez, Maria Jesus ^b   San Félix, Ana ^b   Velázquez, Sonsoles ^b   Camarasa, Maria José ^b   Balzarini, Jan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARTIC ACID; DELAVIRDINE; DNA POLYMERASE; EMIVIRINE; GLUTAMINE; GLYCINE; LYSINE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; PHENYLALANINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TYROSINE; VIRUS ENZYME;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; ENZYME ANALYSIS; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS RECOMBINANT; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0035261907     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0742     Document Type: Article

References (29)

1. 1,2,3-Triazole-[2′,5′-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3′-spiro-5″-(4″-amino-1″,2″- oxathiole-2″,2″-dioxide) (TSAO) analogues: Synthesis and anti-HIV-1 activity
2. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide] (TSAO)
3. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy
4. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase
5. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″amino-1″,2″-oxathiole-2″,2″-dioxide)]-beta- D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors
6. Sensitivity of (138 Glu → Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors
7. Metabolism and pharmacokinetics of the anti-HIV-1-specific inhibitor [1-[2′,5′-bis-O-(tertbutyldimethylsilyl)-beta-D-ribofuranosyl] -3-N-methyl-thymine]-3′spiro-5″-(4″-amino-1″, 2″-oxathiole-2″,2″-dioxide)
8. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3′-spiro-5″-(4″-amino-1″,2″-oxathiole- 2″,2″-dioxide)thymine (TSAO-T)
9. 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide) pyrimidine (TSAO) nucleoside analogues: Highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase
10. [2′,5′-Bis-O-(tert-butyldimethylsilyl)]-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1
11. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase
12. 3′-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: Synthesis and antiviral activity of [2′-5′-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3′-spiro-5″-[4″-amino-1″,2″- oxathiole-2″,2″-dioxide] (TSAO) pyrimidine nucleosides
13. HIV-1 reverse transcriptase/ribonuclease H: High level expression in Escherichia coli from a plasmid constructed using the polymerase chain reaction
14. What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections?
15. The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer
16. A two plasmid co-expression system in Escherichia coil for the production of virion-like reverse transcriptase of the human immunodeficiency virus type 1
17. Resistance of HIV-1 reverse transcriptase against [2′,5′-bis-O-(tert-butyldimethylsilyl)3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)] (TSAO) derivatives is determined by the mutation Glu138 → Lys on the p51 subunit
18. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
19. Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse trascriptase
20. TSAO analogues: Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3′-spiro-5″-(4″-amino-1″,2″-oxathiole- 2″,2″-dioxide) pyrimidine and pyrimidine-modified nucleosides
21. Synthesis of [1-[2′,5′-bis-O-(tert-butyldimethylsilyl)beta-D-xylo- and -D-ribofuranosyl]thymine]-3′-spiro-5″-[4″-amino-1″, 2″-oxathiole 2″,2″-dioxide] (TSAO). A novel type of specific ant-HIV agents
22. Identification of a putative binding site for TSAO-T derivatives at the p51/p66 interface of HIV-I reverse transcriptase
23. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[spiro[4″-amino-2″,2″-dioxo-1″,2″-oxathiole- 5″,3′-[2′, 5′-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3- ethylthymine
24. Managing resistance to anti-HIV drugs: An important consideration for effective disease management
25. Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs
26. Presence of TSAO-resistant virus strains in TSAO-unexperienced HIV patients
27. G → A hypermutation of the human immunodeficiency virus type 1 genome: Evidence for dCTP pool imbalance during reverse transcription